Tests pioglitazone and empagliflozin together for fatty liver in type 2 diabetes
Tests two diabetes drugs together in adults with type 2 diabetes and fatty liver.
Key facts
- Who runs it
- Seoul National University Bundang Hospital
- Where
- Seongnam-si, South KoreaSee the site
- Trial code
- Registry title
- Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 120 people, planned
- Started
- 1 Jan 2025
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- Pioglitazone 15 MG [Actos]
- Empagliflozin 10 MG [Jardiance]
- Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
- Record updated
- 25 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes that is not well controlled and with fatty liver linked to metabolic problems. It tests two diabetes drugs, pioglitazone and empagliflozin, taken together.
- Age
- 20 years or older.
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with HbA1c between 7% (53 mmol/mol) and 10% (86 mmol/mol). Fatty liver seen on Fibroscan within the past 3 months, with CAP of at least 268 dB/m. At least one metabolic problem is also needed, such as large waist, high blood pressure, high triglycerides, low HDL-cholesterol, HOMA-IR of at least 2.5, or CRP of at least 2 mg/L.
- Earlier treatment
- Must be taking metformin alone, metformin with a sulfonylurea, metformin with a DPP-4 inhibitor, or triple therapy including metformin. The sulfonylurea will be stopped at enrolment. Diabetes or metabolic medicines must not have changed in the past 3 months. No GLP-1 receptor agonists, SGLT2 inhibitors, rosiglitazone, vitamin E or ursodeoxycholic acid in the past 3 months.
- Biomarker or test result
- Fibroscan with a controlled attenuation parameter (CAP) of at least 268 dB/m within the past 3 months. HbA1c between 7% (53 mmol/mol) and 10% (86 mmol/mol).
Main reasons for not taking part
- Insulin treatment or type 1 diabetes
- Other causes of fatty liver, such as hepatitis B, hepatitis C or alcoholic fatty liver
- Severe liver or kidney failure, or dialysis
- Heart failure, or cancer including bladder cancer
- Pregnancy or planning to become pregnant
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Adults aged 20 years or older
- Patients with inadequately controlled type 2 diabetes mellitus, defined as HbA1c between 7% and 10%, who are currently treated with either:; Combination therapy of metformin and a sulfonylurea, or; Combination therapy of metformin and a DPP-4 inhibitor, or; Metformin monotherapy, or; Triple therapy (including metformin) provided that sulfonylurea will be discontinued upon study enrollment
- Evidence of hepatic steatosis within the past 3 months, confirmed by Fibroscan with a controlled attenuation parameter (CAP) ≥ 268 dB/m (consistent with S2 or greater [≥10% hepatocyte steatosis] according to the 2024 EASL-EASD-EASO guidelines)
- Presence of at least one of the following metabolic abnormalities:; Waist circumference ≥90 cm for men or ≥85 cm for women; Blood pressure ≥130 mmHg systolic or ≥85 mmHg diastolic, or use of antihypertensive medication; Serum triglycerides ≥150 mg/dL or current use of lipid-lowering agents; HDL-cholesterol ≤45 mg/dL for men or ≤50 mg/dL for women; HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) ≥2.5; Serum C-reactive protein (CRP) ≥2 mg/L
- No changes in anti-diabetic or metabolic medications within the past 3 months, unless the changes are deemed by the investigator not to affect study outcomes
Who cannot take part
- Patients receiving insulin therapy or diagnosed with type 1 diabetes mellitus
- Use of the following medications within the past 3 months: GLP-1 receptor agonists, SGLT2 inhibitors, rosiglitazone (TZD), vitamin E, or ursodeoxycholic acid (UDCA)
- Use of medications known to induce hepatic steatosis, including valproic acid, estrogen, tamoxifen, amiodarone, or chloroquine
- Presence of secondary causes of hepatic steatosis unrelated to metabolic dysfunction, such as hepatitis B, hepatitis C, or alcoholic fatty liver disease
- Presence of hepatocellular carcinoma, active malignancy, or metastatic cancer
- History of or active bladder cancer
- History of heart failure or current diagnosis of heart failure
- Presence of terminal illnesses
- History of gallstone disease, chronic pancreatitis, or acute pancreatitis
- Known hypersensitivity to the active ingredients or excipients of the study medications
- History of diabetic ketoacidosis
- Severe organ failure, defined as:; Liver failure: AST or ALT > 5 times the upper normal limit (UNL), serum albumin < 3.2 g/dL, platelet count < 60,000/µL, or Child-Pugh-Turcotte stage B or C; Renal failure: Serum creatinine ≥ 2.0 mg/dL, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² (CKD-EPI formula), or patients with end-stage renal disease or on dialysis
- Underweight patients (body mass index [BMI] < 18.5 kg/m²)
- Pregnant women or women planning to become pregnant
Where in South Korea
- Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Soo Lim DrTaking people
About the trial
What the trial wants to find out
This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is scarce. This study seeks to determine whether the combination therapy yields additive improvements in hepatic steatosis, inflammation, and fibrosis, potentially offering a new therapeutic strategy for diabetic patients with fatty liver disease.
The 3 groups in the trial
- PioglitazoneTreatment being tested
Pioglitazone 15mg
Treatment: Empagliflozin 10 MG [Jardiance]
- EmpagliflozinTreatment being tested
Empagliflozin 10mg
Treatment: Pioglitazone 15 MG [Actos]
- Pioglitazone & EmpagliflozinTreatment being tested
Pioglitazone 15mg + Empagliflozin 10mg
Treatment: Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Pioglitazone and Empagliflozin Combination Therapy in Type 2 Diabetes Patients With Metabolic Dysfunction-Associated Fatty Liver Disease
- Plain-language title
- Tests pioglitazone and empagliflozin together for fatty liver in type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 May 2025